Objetivo
- Development of microspheres for the removal of endotoxins, cytokines TNFalpha and IL-1beta, exotoxin SEB, bilirubin and toxins of liver failure
- Development of biodegradable endotoxin binding microspheres as a tool of higher safety of MDS.
- Development of MDS-device including the optimization of the plasma filter and the establishment of an intelligent software and hardware to accomplish high safety standards and facilitated handling
- In vivo testing and clinical testing of MDS in specific animal models (endotoxin shock and liver failure) and patients suffering from MOF, respectively
Multi organ failure (MOF), very common in septic shock patients of any age, is a multifactorial disease involving nearly all organs and systems of the human being. Its average mortality is in a range of 40-50%, and prognosis has not significantly improved during the last 10 years. The course of MOF is characterized by complex structure, initiated by endotoxins, followed by a cascade-like activation of different cells and systems. The main objective of this proposal is to establish a therapeutically system which is able to influence the multi-factorial pathophysiology at 3 different levels. The first level concentrates on the removal of free soluble endotoxins and exotoxins from blood. The second level is concerned with the removal of the principal cytokines, TNF-a and IL-1 +, by specific adsorbents. Finally, the third level includes the therapy of acute liver failure, including hepato-renal syndrome. This three step concept is based on a very recently introduced blood purification technology: the WMicrospheres based Detoxification System"(MDS). MDS is a newly developed adsorptive technology, based on a simultaneous adsorption/filtration technique, which employs microspheres in the size of 2-4,um. A suspension containing the microspheres is recirculated very rapidly and is mixed into filtrated plasma from the patient, thereby removing undesirable substances. Due to the very efficient structure of the adsorbent particles, only relatively small amounts are required, which can be applied in combinationor in sequence.
The microspheres developed are selective (use of immobilized functional groups) or specific (use of immobilized antibodies) for the removal of endotoxins, exotoxins, TNF-, IL-1 +, live rrelated substances such asphenols, thiols, aromatic amino acids or other lipophilic substances as well as protein bound substances such as bilirubin. The MDS will be designed for continuous use in intensive care units. A plasmafilter specifically designed to offer optimal conditions for continuous filtration is integrated in the blood circuit. Special sensors, the possibleuse of biodegradable microspheres, the application of magnetic microspheres, which can be replaced without any loss of plasma, and the integration of a centrifugal pump to achieve fast recirculation of the microsphere suspension make MDS a high-tech device in blood purification therapy. The system can be combined with continuous filtration in the secondary circuit, removing uraemic substances including other water-soluble toxins in the middle molecular range. In future, additional possibilities such as the use of hepatocytes or other cells could transform MDS into a bioartificial system. The project is an interdisciplinary one, which includes the development of technically very advanced materials and equipment, which will be tested in vivo and clinically during the duration of the project. It also opens new ways of specific blood purification therapy in other fields of medicine such as metabolic, autoimmune or cancer diseases. These ambitious goals can only be achieved by an international cooperation at European level. The project proposal is designed for a fast transfer of the new technology in industrial production, involving clinical testing but also partners with industrial experience. In conclusion, the project offers European industry new perspectives to compete against industries from the USA and Japan by establishing a complete new technology for blood purification therapy.
Ámbito científico (EuroSciVoc)
CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véas: El vocabulario científico europeo..
CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véas: El vocabulario científico europeo..
- ciencias agrícolas biotecnología agrícola
- ciencias médicas y de la salud medicina básica fisiología fisiopatología
- ciencias médicas y de la salud medicina clínica medicina intensiva
- ciencias médicas y de la salud medicina clínica oncología
- ciencias naturales ciencias químicas química orgánica aminas
Para utilizar esta función, debe iniciar sesión o registrarse
Programa(s)
Programas de financiación plurianuales que definen las prioridades de la UE en materia de investigación e innovación.
Programas de financiación plurianuales que definen las prioridades de la UE en materia de investigación e innovación.
Tema(s)
Las convocatorias de propuestas se dividen en temas. Un tema define una materia o área específica para la que los solicitantes pueden presentar propuestas. La descripción de un tema comprende su alcance específico y la repercusión prevista del proyecto financiado.
Las convocatorias de propuestas se dividen en temas. Un tema define una materia o área específica para la que los solicitantes pueden presentar propuestas. La descripción de un tema comprende su alcance específico y la repercusión prevista del proyecto financiado.
Convocatoria de propuestas
Procedimiento para invitar a los solicitantes a presentar propuestas de proyectos con el objetivo de obtener financiación de la UE.
Datos no disponibles
Procedimiento para invitar a los solicitantes a presentar propuestas de proyectos con el objetivo de obtener financiación de la UE.
Régimen de financiación
Régimen de financiación (o «Tipo de acción») dentro de un programa con características comunes. Especifica: el alcance de lo que se financia; el porcentaje de reembolso; los criterios específicos de evaluación para optar a la financiación; y el uso de formas simplificadas de costes como los importes a tanto alzado.
Régimen de financiación (o «Tipo de acción») dentro de un programa con características comunes. Especifica: el alcance de lo que se financia; el porcentaje de reembolso; los criterios específicos de evaluación para optar a la financiación; y el uso de formas simplificadas de costes como los importes a tanto alzado.
Coordinador
3500 Krems
Austria
Los costes totales en que ha incurrido esta organización para participar en el proyecto, incluidos los costes directos e indirectos. Este importe es un subconjunto del presupuesto total del proyecto.